Ron Chen
VP of Finance and Corporate ControllerMr. Ron Chen is VP of Finance and Corporate Controller of Rein Therapeutics Inc (formerly known as Aileron Therapeutics, Inc). since December 2023. Mr. Chen is a Licensed Certified Public Accountant (CPA) in Massachusetts with over 17 years of experience in accounting and finance. Prior to joining Aileron, Ron held the position of Corporate Controller at Reata Pharmaceuticals, overseeing financial operations. During his tenure, Reata successfully initiated commercialization following FDA approval of its first product and it was acquired by Biogen in July 2023. From February 2020 to April 2022, he served as Assistant Controller at Pear Therapeutics, where he contributed to the company’s successful public listing through a special purpose acquisition company (SPAC) deal in 2021. From March 2017 to February 2020, Ron served as the technical accounting and SEC reporting lead at Bioverativ and later at Sanofi following Bioverativ’s acquisition in January 2018. At Sanofi, a global leader in immunology, Ron played a key role in managing financial operations and reporting for a major pharmaceutical entity. Earlier in his career, Ron worked as an auditor at Ernst & Young LLP, one of the world’s largest professional services firms, where he honed his expertise in accounting and financial auditing. He holds a Bachelor of Science degree in Finance from Nanjing University in China and a Master of Science degree in Accounting from Boston College.
Positions
- Company NameRein Therapeutics Inc.Stock CodeRNTXPositionVP of Finance and Corporate ControllerColleagues
- JBJames Brian WindsorCEO, President & Director
- JHJosef H. von RickenbachIndependent Chairman
- TMTimothy M. CunninghamInterim CFO & Principal Accounting Officer
- CMCory M. HogaboamChief Scientific Officer
- JFJennifer FaigleCounsel
- RJReinhard J. AmbrosIndependent Lead Director
- AAAlan A. MussoIndependent Director
- WCWilliam Carl FaireyIndependent Director
